Cited by 1,249Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis MechanismsCerebral Venous Sinus Thrombosis

The DOI matches its Crossref record; 205 of the 208 references it cites were found in a registry or an index.

Antithrombotic Therapy for Venous Thromboembolic Disease

Büller, Harry R., Agnelli, Giancarlo, Hull, Russel D., Hyers, Thomas M., Prins, Martin H., Raskob, Gary E.·2004·Chest

DOI 10.1378/chest.126.3_suppl.401s

Open this paper in CoChat — free account

Abstract

This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key recommendations in this chapter are the following: for patients with objectively confirmed deep vein thrombosis (DVT), we recommend short-term treatment with subcutaneous (SC) low molecular weight heparin (LMWH) or, alternatively, IV unfractionated heparin (UFH) [both Grade 1A]. For patients with a high clinical suspicion of DVT, we recommend treatment with anticoagulants while awaiting the outcome of diagnostic tests (Grade 1C+). In acute DVT, we recommend initial treatment with LMWH or UFH for at least 5 days (Grade 1C), initiation of vitamin K antagonist (VKA) together with LMWH or UFH on the first treatment day, and discontinuation of heparin when the international normalized ratio (INR) is stable and > 2.0 (Grade 1A). For the duration and intensity of treatment for acute DVT of the leg, the recommendations include the following: for patients with a first episode of DVT secondary to a transient (reversible) risk factor, we recommend long-term treatment with a VKA for 3 months over treatment for shorter periods (Grade 1A). For patients with a first episode of idiopathic DVT, we recommend treatment with a VKA for at least 6 to 12 months (Grade 1A). We recommend that the dose of VKA be adjusted to maintain a target INR of 2.5 (INR range, 2.0 to 3.0) for all treatment durations (Grade 1A). We recommend against high-intensity VKA therapy (INR range, 3.1 to 4.0) [Grade 1A] and against low-intensity therapy (INR range, 1.5 to 1.9) compared to INR range of 2.0 to 3.0 (Grade 1A). For the prevention of the postthrombotic syndrome, we recommend the use of an elastic compression stocking (Grade 1A). For patients with objectively confirmed nonmassive PE, we recommend acute treatment with SC LMWH or, alternatively, IV UFH (both Grade 1A). For most patients with pulmonary embolism (PE), we recommend clinicians not use systemic thrombolytic therapy (Grade 1A). For the duration and intensity of treatment for PE, the recommendations are similar to those for DVT.

Integrity signals

Registry

Crossref · 10.1378/chest.126.3_suppl.401s

Cites

205 of 205 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
Lee, A. Y. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M. H., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025313 · Cited by 2,528
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,094
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
Decousus, H., Leizorovicz, A., Parent, F., Page, Y., Tardy, B., Girard, P., Laporte, S., Faivre, R., Charbonnier, B., Barral, F.-G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380701 · Cited by 1,702
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
ANTICOAGULANT DRUGS IN THE TREATMENT OF PULMONARY EMBOLISM
Barritt, D. W., & Jordan, S. C. (1960) · The Lancet · doi:10.1016/s0140-6736(60)92299-6 · Cited by 1,362
Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism
Heit, J. A., Mohr, D. N., Silverstein, M. D., Petterson, T. M., O’Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.761 · Cited by 1,348
A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis
Levine, M., Gent, M., Hirsh, J., Leclerc, J. E., Anderson, D. R., Weitz, J. I., Ginsberg, J. S., Turpie, A. G. G., Demers, C., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341101 · Cited by 1,186
Hemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G. E., Landefeld, S., & Kearon, C. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.108s · Cited by 1,129
Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home
Koopman, M. M. W., Prandoni, P., Piovella, F., Ockelford, P., Brandjes, D. P. M., van der Meer, J., Gallus, A. S., Simonneau, G., Chesterman, C., Prins, M. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341102 · Cited by 1,105
A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism
Kearon, C., Gent, M., Hirsh, J., Weitz, J. I., Kovacs, M. J., Anderson, D. R., Turpie, A. G. G., Green, D., Ginsberg, J. S., Wells, P. S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,057

Show all 208 references

Research works printed but not linked: 7

Hull, 2002, A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium [abstract], Blood, 100, 148a
Hull, 2001, Safety and efficacy results for a study investigating the long-term out-of-hospital treatment of patients with proximal-vein thrombosis using subcutaneous low-molecular-weight heparin versus warfarin [abstract], Thromb Haemost
Hull, 2003, A randomised trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer [abstract], Thromb Haemost, P137a
Prandoni, 2002, Below-knee compression stockings for prevention of the post-thrombotic syndrome: a randomized study [abstract], Pathophysiol Haemost Thromb, 32, 72
Morl, 1986, Treatment of postthrombotic syndrome with a mixture of enzymes [in German], Therapiewoche, 36, 2443
Massoure, 2000, Thromboses veineuses profondes des members supérieurs, J Mal Vasc, 25, 250
Pegis, 1997, Thrombolyse in situ dans le traitement des thromboses veineuses d'effort du membre supérieur, J Mal Vasc, 22, 187

Sorted by citations

Items 501–600 of 1,000

Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long‐term secondary prevention of venous thromboembolism
Wåhlander, K., Eriksson, H., Lundström, T., Clason, S. B., Wall, U., Nyström, P. O., Wessman, P., Schulman, S., & THRIVE III Investigators (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.05960.x · Cited by 19
“Recent treatment guidelines (Büller et al, 2004) support extended secondary prevention with vitamin K antagonists (VKA; e.g. warfarin) for 6–12 months in patients with a first episode of deep vein thrombosis (DVT) who have the factor V Leiden or prothrombin gene G20210A mutation or deficiencies of…”
Background
Chronic Obstructive Pulmonary Disease in Patients With Acute Symptomatic Pulmonary Embolism
Fernández, C., Jiménez, D., de Miguel‐Díez, J., Sánchez, D. M., Díaz, G., & Sueiro, A. (2009) · Archivos de Bronconeumología · doi:10.1016/s1579-2129(09)72419-x · Cited by 18
Misconceptions, Challenges, Uncertainty, and Progress in Guideline Recommendations
Kunz, R., Djulbegović, B., Schünemann, H. J., Stanulla, M., Muti, P., & Guyatt, G. H. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.04.005 · Cited by 18
Risk factors and complications of subconjunctival hemorrhages in patients taking warfarin
Leiker, L. L., Mehta, B. H., Pruchnicki, M. C., & Rodis, J. L. (2009) · Optometry · doi:10.1016/j.optm.2008.10.018 · Cited by 18
Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery
Dahl, O. E., Eriksson, B. I., Agnelli, G., Cohen, A. T., Mouret, P., Rosencher, N., Panfilov, S., Bylock, A. L., & Andersson, M. V. (2005) · Clinical Drug Investigation · doi:10.2165/00044011-200525010-00006 · Cited by 18
Duration of vitamin K antagonist therapy for venous thromboembolism: a systematic review of the literature
Streiff, M. B., Segal, J. B., Tamariz, L. J., Jenckes, M. W., Bolger, D. T., Eng, J., Krishnan, J. A., & Bass, E. B. (2006) · American Journal of Hematology · doi:10.1002/ajh.20691 · Cited by 17
Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients
Kumar, D. K., Madhan, S., Balachander, J., Chandran, B. V. S., Thamijarassy, B., & Chandrasekaran, A. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.02.006 · Cited by 17
“Oral anticoagulants, including warfarin and acenocoumarol, are most widely prescribed for prevention of thromboembolic events in patients with prosthetic valves, atrial fibrillation, deep vein thrombosis, and coronaryheart diseases [1–5].”
Background
The Cavovarus Foot in Hereditary Motor and Sensory Neuropathies
Georgiadis, A. G., Spiegel, D. A., & Baldwin, K. D. (2015) · JBJS Reviews · doi:10.2106/jbjs.rvw.o.00024 · Cited by 17
Diagnosis and Management of Venous Thromboembolism
Minichiello, T., & Fogarty, P. F. (2008) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.12.001 · Cited by 17
“Although there are no prospective randomized studies evaluating the efficacy of thrombolysis in patients with massive PE, the extremely high in-hospital mortality rate (approaching 30%) and potentially improved outcomes on subgroup analysis [44] have led to recommendations for use of thrombolysis in this setting [40].”
BackgroundInfluential
Shear Wave Induced Resonance Elastography of Venous Thrombi: A Proof-of-Concept
Cédric Schmitt, A., Montagnon, E., Henni, A. H., Qi, S., & Cloutier, G. (2012) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2012.2231093 · Cited by 17
“In contrast, for a chronic thrombus older than six months, the therapy is different and consists of oral anticoagulants alone because heparin can induce bleeding complications or nondesirable anti-inflammatory effects [5].”
Background
Prognosis after Cryptogenic Cerebral Ischemia in Patients with Coagulopathies
Weber, R., Goertler, M., Benemann, J., Diener, H., & Weimar, C. (2009) · Cerebrovascular Diseases · doi:10.1159/000251172 · Cited by 17
“Oral anticoagulation is the treatment of choice for 6–12 months after a first episode of acute venous thromboembolism in patients with documented thrombophilia. Long-term anticoagulation treatment is recommended if recurrent venous thromboembolism occurs or in patients who have documented antiphospholipid antibodies o…”
Background
Are All Low Molecular Weight Heparins Equivalent in the Management of Venous Thromboembolism?
Fareed, J., Jeske, W. P., Fareed, D., Clark, M., Wahi, R., Adıgüzel, C., & Hoppensteadt, D. (2007) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029608319881 · Cited by 17
“After acute DVT, there is a high risk of extension of thrombosis or recurrence of VTE, with the frequency estimated at 15% to 50%.(18) For this reason, extended thromboprophylaxis is recommended.”
BackgroundInfluential
Anticoagulant therapy after venous thromboembolism and 10-year mortality
Larsen, T. B., Lip, G. Y. H., & Gorst‐Rasmussen, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.01.190 · Cited by 17
“International guidelines for secondary prevention after VTE published during the last decade [8–12] have formed the basis for the Danish guidelines.”
Background
Antipsychotic drugs and the risk of recurrent venous thromboembolism: A prospective cohort study
Mollard, L.-M., Mao, R. L., Tromeur, C., Moigne, E. L., Gouillou, M., Pan‐Petesch, B., Delluc, A., Couturaud, F., & Lacut, K. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.02.030 · Cited by 17
Deep Venous Thrombosis Management Following Traumatic Brain Injury
Carlile, M. C., Yablon, S. A., Mysiw, W. J., Frol, A. B., Lo, D., & Diaz-Arrastia, R. R. (2006) · Journal of Head Trauma Rehabilitation · doi:10.1097/00001199-200611000-00003 · Cited by 17
Heparin‐induced thrombocytopenia from venous thromboembolism treatment
Begelman, S. M., Hursting, M. J., Aghababian, R. V., & McCollum, D. A. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01573.x · Cited by 17
Immobilization resulting from chronic medical diseases: a new risk factor for recurrent venous thromboembolism in anticoagulated patients
Prandoni, P., Villalta, S., Tormene, D., Spiezia, L., & Pesavento, R. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02645.x · Cited by 17
Outpatient Management of Stable Acute Pulmonary Embolism: Proposed Accelerated Pathway for Risk Stratification
AlMahameed, A. T., & Carman, T. L. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.08.010 · Cited by 17
Update on Anticoagulant Medications for the Interventional Radiologist
Mehta, R. P., & Johnson, M. S. (2006) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000209226.54671.42 · Cited by 17
Inferior Vena Cava Filters in Venous Thromboembolism
Weichman, K. I., & Ansell, J. (2006) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.04.002 · Cited by 17
Quality of INR Control and Outcomes Following Venous Thromboembolism
Gallagher, A. M., de Vries, F., Plumb, J. M., Haß, B., Clemens, A., & van Staa, T. P. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029611426139 · Cited by 16
Duration of Anticoagulation: Applying the Guidelines and Beyond
Bauer, K. A. (2010) · Hematology · doi:10.1182/asheducation-2010.1.210 · Cited by 16
Out of sight, out of mind: an audit of inferior vena cava filter insertion and clinical follow up in an A ustralian institution and literature review
Tan, X. L., Tam, C. S. L., McKellar, R. P. V., Nandurkar, H. H., & Bazargan, A. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02869.x · Cited by 16
Assessment of IVC filter efficacy in prevention of pulmonary thrombo-embolism by 99mTc-MAA lung perfusion scintigraphy—A case series and review of literature
Vijayvergiya, R., Mittal, B. R., Grover, A., Hariram, V., Bhattacharya, A., & Singh, B. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.08.120 · Cited by 16
Deep Vein Thrombosis of Lower Extremity: Direct Intraclot Injection of Alteplase Once Daily with Systemic Anticoagulation—Results of Pilot Study
Chang, R. C.-A., Chen, C. C., Kam, A. W., Mao, E., Shawker, T. H., & Horne, M. K. (2008) · Radiology · doi:10.1148/radiol.2461062076 · Cited by 16
Catheter-Directed Thrombolysis for Acute Iliofemoral Deep Venous Thrombosis
Liu, F., Lü, P., & Jin, B. (2011) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2010.12.002 · Cited by 16
Optional Vena Cava Filters: What, Why, and When
Kaufman, J. A. (2007) · Vascular · doi:10.2310/6670.2007.00061 · Cited by 16
Thrombophilia in the young.
Nowak‐Göttl, U., Kurnik, K., Krümpel, A., & Stoll, M. (2008) · PubMed · Cited by 16
Venous Thromboembolism after Retrieval of Inferior Vena Cava Filters
Yavuz, K., Geyik, S., Hoppe, H., Kolbeck, K. J., & Kaufman, J. A. (2008) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2007.11.016 · Cited by 16
Incidence of deep vein thrombosis in patients undergoing breast reconstruction with autologous tissue transfer
Konoeda, H., Yamaki, T., Hamahata, A., Ochi, M., Osada, A., Hasegawa, Y., Kirita, M., & Sakurai, H. (2016) · Phlebology The Journal of Venous Disease · doi:10.1177/0268355516680427 · Cited by 16
“4%.(24) With a complete understanding of this condition, we need to introduce chemoprophylaxis in the field of plastic and reconstructive surgery.”
Background
Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation—The EWA study
Jaakkola, S., Nuotio, I. O., Kiviniemi, T., Virtanen, R., Issakoff, M., & Airaksinen, J. K. E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175975 · Cited by 16
Thrombophilia
Heit, J. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00014-2 · Cited by 16
Evaluation of three commercial ELISA kits for anticardiolipin and anti‐beta2‐glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome
Decavele, A.-S. C., Schouwers, S., & Devreese, K. M. J. (2010) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2010.01259.x · Cited by 16
“False-negative (FN) results have serious consequences for patients suspected for APS because they need long-term anticoagulation to prevent recurrences (Buller et al., 2004).”
Background
Clinically suspected acute recurrent pulmonary embolism: A diagnostic challenge
Erp, J. M. K., Söhne, M., Tick, L. W., Kruip, M. J. H. A., Ullmann, E. F., Kramer, M. H. H., Buller, H. R., Prins, M. H., Leebeek, F. W. G., Huisman, M. V., et al. (2007) · Thrombosis and Haemostasis · doi:10.1160/th06-11-0635 · Cited by 16
Fondaparinux Sodium
Robinson, D. M., & Wellington, K. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505050-00007 · Cited by 16
Successful Thrombolysis of a Stroke with a Pulmonary Embolism in a Young Woman
Pelletier, M., Bugeaud, R., Ibrahim, R., Morency, G., & Kouz, S. (2009) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2009.02.033 · Cited by 16
Thromboprophylaxis in medical–surgical critically ill patients
Crowther, M. A., & Cook, D. J. (2008) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32830c484d · Cited by 16
Clinical pathways as a healthcare tool: design, implementation and assessment of a clinical pathway for lower-extremity deep venous thrombosis
Verdu, A., Maestre, A. M., López, P., Gil, V., Martín-Hidalgo, A., & Castano, J. A. (2009) · BMJ Quality & Safety · doi:10.1136/qshc.2007.023218 · Cited by 15
Venous Thromboembolism: Diagnosis and Treatment
Nogueira, R. F., Botelho, L. F., & da Silva, R. C. T. (2017) · Springer eBooks · doi:10.1007/978-3-319-46059-8_12 · Cited by 15
A Simple Clinical Model Composed of ECG, Shock Index, and Arterial Blood Gas Analysis for Predicting Severe Pulmonary Embolism
Bircan, A., Karadeniz, N., Özden, A., Çakır, M., Varol, E., Oyar, O., & Özaydın, M. (2009) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029609351877 · Cited by 15
“3) ns 3 (25) 9 (75) ns S in lead I 3 (42.”
Inferior Vena Cava Agenesia and a Massive Bilateral Iliofemoral Venous Thrombosis
Vučičević, Ž., Degoricija, V., Alfirević, Z., & Sharma, M. (2008) · Angiology · doi:10.1177/0003319707305350 · Cited by 15
“The optimum choice and duration of anticoagulation, related to particular thromboembolic diseases, were given by the evidence-based guidelines.(17) No specific suggestions were made for thrombotic events that are primarily associated with anatomical anomalies.”
Background
Home Therapy With LMWH in Deep Vein Thrombosis: Randomized Study Comparing Single and Double Daily Administrations
Bellosta, R., Ferrari, P., Luzzani, L., Carugati, C., Cossu, L. G., Talarico, M., & Sarcina, A. (2007) · Angiology · doi:10.1177/0003319707301757 · Cited by 15
Treatment of Venous Thromboembolism in Cancer Patients
Lee, A. Y. Y., & Levine, M. N. (2005) · Cancer Control · doi:10.1177/1073274805012003s04 · Cited by 15
Deficits in Discharge Documentation in Patients Transferred to Rehabilitation Facilities on Anticoagulation: Results of a Systemwide Evaluation
Gándara, E., Moniz, T. T., Ungar, J. P., Lee, J., Chan‐Macrae, M., O’Malley, T. A., & Schnipper, J. L. (2008) · The Joint Commission Journal on Quality and Patient Safety · doi:10.1016/s1553-7250(08)34057-4 · Cited by 15
Massive Retroperitoneal Hematoma During Enoxaparin Treatment of Pulmonary Embolism After Primary Total Hip Arthroplasty
Lee, M. C., Nickisch, F., & Limbird, R. S. (2006) · The Journal of Arthroplasty · doi:10.1016/j.arth.2006.01.018 · Cited by 15
“However, enoxaparin and UH share an incidence of major bleeding, such as retroperitoneal hematoma, of up to 5% [2].”
Background
Retrievable vena cava filters: clinical experience
Dentali, F., Ageno, W., & Imberti, D. (2006) · Current Opinion in Internal Medicine · doi:10.1097/01.mcp.0000239544.17208.5c · Cited by 15
Venous Thrombotic Events in Cancer: The Bottom Line
Horton, J. (2005) · Cancer Control · doi:10.1177/1073274805012003s06 · Cited by 15
Pentasaccharides for the treatment of deep vein thrombosis
Brandão, G. M. S., Junqueira, D. R., Rollo, H. A., & Sobreira, M. L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011782.pub2 · Cited by 13
Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial
Kurtoğlu, M., Köksoy, C., Ekim, H., Akçalı, Y., Karabay, Ö., & Filizcan, U. (2010) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2010.06.070 · Cited by 14
Anti-factor Xa Activity of Enoxaparin for Thromboprophylaxis in Nonsurgical Patients Is Dependent on Body Mass
Jiménez, D., Díaz, G., Iglesias, A., César, J. M., Garciá‐Avello, A., Sánchez, D. M., Escobar, C., Vidal, R., & Sueiro, A. (2008) · Archivos de Bronconeumología · doi:10.1016/s1579-2129(09)60003-3 · Cited by 14
Cancer and thrombosis: an increasingly important association
Korte, W. C. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-007-0376-y · Cited by 14
“These results are now also reflected in the American College of Chest Physicians (ACCP) guidelines, recommending the use of LMWH in cancer patients for both, acute treatment as well as longterm prophylaxis of VTE [40].”
BackgroundResult
Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?
Spyropoulos, A. C., Preblick, R., Kwong, W. J., Lingohr-Smith, M., & Lin, J. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029616680475 · Cited by 14
Intra-alveolar epsilon-aminocaproic acid for the control of post-extraction bleeding in anticoagulated patients: randomized clinical trial
da Silva, R. V., Gadelha, T., Luiz, R. R., & Torres, S. R. (2018) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2018.02.013 · Cited by 14
Alternatives to Warfarin-The Next Generation of Anticoagulants
Kanagasabapathy, P., Chowdary, P., & Gatt, A. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00197.x · Cited by 14
“4% [31].”
Venous Thromboembolic Disease
Suwanabol, P. A., & Hoch, J. R. (2013) · Surgical Clinics of North America · doi:10.1016/j.suc.2013.05.003 · Cited by 14
Management of venous thromboembolism in patients with cancer: role of dalteparin
Linkins, L. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s2132 · Cited by 14
“Despite recommendations based on the results of the CLOT trial (Buller et al 2004), extended duration dalteparin treat-ment of cancer-related VTE has not been widely adopted (pers comm).”
NHG-Standaard Diepe veneuze trombose
Oudega, R., van Weert, H. C. P. M., Stoffers, J., Sival, P. P. E., Schure, R. I., Delemarre, J., & Eizenga, W. H. (2009) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-6614-9_2 · Cited by 14
El síncope como forma de presentación de la embolia de pulmón: valor pronóstico
Jiménez, D., Díaz, G., Valle, M., Martí, D., Escobar, C., Vidal, R., Picher, J., & Sueiro, A. (2005) · Archivos de Bronconeumología · doi:10.1157/13076969 · Cited by 14
Determining Indications for Care Common to Competing Guidelines by Using Classification Tree Analysis: Application to the Prevention of Venous Thromboembolism in Medical Inpatients
Bosson, J., & Labarère, J. (2006) · Medical Decision Making · doi:10.1177/0272989x05284105 · Cited by 14
Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin
Hyers, T. M., Spyropoulos, A. C., & For the INNOVATE Investigators (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0020-1 · Cited by 14
“In all of these settings, the once daily dosing regimen of tinzaparin offers efficacy and convenience [29].”
Background
Treatment of venous thrombosis at unusual sites
McBane, R. D., & Wysokiński, W. E. (2008) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-008-0015-z · Cited by 14
Prognostic Role of Heart-type Fatty Acid Binding Protein in Pulmonary Embolism: a Meta-analysis
Liu, M., Yuan, X., Qiu, X., Shan, X., Lin, D., & Zhu, L. Y. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.10.007 · Cited by 14
Venous thromboembolism risk and management in women with cancer and thrombophilia
Prandoni, P. (2005) · Gender Medicine · doi:10.1016/s1550-8579(05)80062-2 · Cited by 14
Extensive deep vein thrombosis as a complication of testicular cancer treated with the BEP protocol (bleomycin, etoposide and cisplatin): case report
Mano, M. S., Guimarães, J. L., Sutmöller, S. F. M. C., Reiriz, A. B., Sutmöller, C. S. S. C., & Leo, A. D. (2006) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802006000600009 · Cited by 14
Deep Venous Thrombosis: The Opportunity at Hand
Vedantham, S. (2009) · American Journal of Roentgenology · doi:10.2214/ajr.09.3214 · Cited by 14
“Before 2008, these differences were embodied in conflicting recommendations of the American College of Chest Physicians (ACCP) 2004 consensus guidelines (against the use of catheter-directed intrathrombus thrombolysis for primary PTS prevention) and a 2006 position statement of the Society of Interventional Radiology…”
Background
The Pharmacoeconomics of Deep Vein Thrombosis Treatment
Shorr, A. F. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.08.012 · Cited by 14
New Anticoagulant Agents: Direct Thrombin Inhibitors
Nutescu, E. A., Shapiro, N. L., & Chevalier, A. (2006) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2005.09.009 · Cited by 14
Introduction
Goodin, S. (2005) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050431 · Cited by 14
Noninvasive Thrombolysis Using Histotripsy Pulsed Ultrasound Cavitation Therapy.
Maxwell, A. D. (2012) · Deep Blue (University of Michigan) · Cited by 14
“I enjoyed your talk, but…”: Evidence-based medicine and the scientific foundation of the American Venous Forum
Meissner, M. H. (2008) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2008.08.029 · Cited by 13
Partielle einseitige Schwellkörperthrombose bei Homozysteinämie
Blaut, S., Schneider, M., Zschuppe, E., Günl, U., & Steinbach, F. (2008) · Der Urologe · doi:10.1007/s00120-008-1650-4 · Cited by 13
Interventions for Deep Vein Thrombosis: Reemergence of a Promising Therapy
Vedantham, S. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.08.007 · Cited by 13
Patient-reported treatment satisfaction measures for long-term anticoagulant therapy
Wild, D. J., Murray, M. I., Shakespeare, A., Reaney, M. D., & von Maltzahn, R. (2008) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.8.3.291 · Cited by 13
Massive Pulmonary Embolism
WILSHER, M. L., & Connell, H. (2007) · Elsevier eBooks · doi:10.1016/b978-075067572-7.50026-6 · Cited by 13
Systematic Review of Real-World Studies Evaluating Characteristics Associated With or Programs Designed to Facilitate Outpatient Management of Deep Vein Thrombosis
Weeda, E. R., & Butt, S. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618811082 · Cited by 13
“Outpatient treatment requires adequate social support.(38-40,45) Patients must be able to attend follow-up visits, have access to anticoagulant treatment, and be able to easily return to the hospital if they were to deteriorate.”
Background
Evaluation of Venous Thromboembolism Recurrence Scores in an Unprovoked Pulmonary Embolism Population: A Post-hoc Analysis of the PADIS-PE trial
Raj, L., Presles, É., Mao, R. L., Robin, P., Sanchez, O., Pernod, G., Bertoletti, L., Jégo, P., Lemarié, C. A., Leven, F., et al. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.03.040 · Cited by 14
Novos anticoagulantes para a profilaxia do tromboembolismo venoso em cirurgias ortopédicas de grande porte
Yoshida, R. D. A., Yoshida, W. B., & Rollo, H. A. (2011) · Jornal Vascular Brasileiro · doi:10.1590/s1677-54492011000200009 · Cited by 13
New diagnostic strategies for pulmonary embolism
Kyrle, P. A., & Eichinger, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60572-3 · Cited by 13
Vena cava filter retrieval in therapeutically anticoagulated patients
Schmelzer, T. M., Christmas, A. B., Taylor, D. A., Heniford, B. T., & Sing, R. F. (2008) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2008.07.032 · Cited by 13
Successful Thrombolysis in Postoperative Patients With Acute Massive Pulmonary Embolism
Zhang, K., Zeng, X., Zhu, C., Xu, L., Fu, X., Jiang, H., Wang, J., & Lu, W. (2012) · Heart Lung and Circulation · doi:10.1016/j.hlc.2012.08.055 · Cited by 13
Comparison of low-molecular-weight-heparin and unfractionated heparin for acute PTE
Chen, L., Ying, K., Hong, W.-J., & Zhou, P. (2005) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.2005.b1195 · Cited by 13
“Acute PTE treatment with subcutaneous LMWH or alternatively IV UH were recommended for treating confirmed non-massive PTE in the guideline in 2004 (Grade 1A) (Buller et al., 2004).”
Method
Thromboses sur cathéter central chez le patient cancéreux
Debourdeau, P., Zammit, C., Pavic, M., Bensaid, B., & Farge, D. (2007) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2007.03.002 · Cited by 13
Thrombolysis for massive pulmonary embolism in pregnancy: a case report
Fasullo, S., Scalzo, S., Maringhini, G., Cannizzaro, S., Terrazzino, G., Paterna, S., & Pasquale, P. D. (2010) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2010.06.016 · Cited by 13
Enfermedad pulmonar obstructiva crónica en pacientes con tromboembolia de pulmón aguda sintomática
Fernández, C., Jiménez, D., de Miguel‐Díez, J., Sánchez, D. M., Díaz, G., & Sueiro, A. (2009) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2008.10.008 · Cited by 13
Portal Vein Thrombosis: An Unexpected Finding in a 28-Year-Old Male With Abdominal Pain
Ferguson, J. L., & Hennion, D. R. (2008) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2008.03.070157 · Cited by 13
Trombose venosa profunda: Mitos e realidades
Familiar, A. D. M. G. E., & Antunes, S. D. (2010) · Revista Portuguesa de Clínica Geral · doi:10.32385/rpmgf.v26i5.10783 · Cited by 12
Ambulating With Pulmonary Artery or Femoral Catheters in Place
Winkelman, C. (2011) · Critical Care Nurse · doi:10.4037/ccn2011556 · Cited by 12
Extended Dalteparin Prophylaxis for Venous Thromboembolic Events
Dranitsaris, G., Stumpo, C., Smith, R. E., & Bartle, W. R. (2009) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03256594 · Cited by 12
Septic Thrombosis of the Inferior Vena Cava Treated with Percutaneous Mechanical Thrombectomy
Burgmans, M. C., Rommes, J. H., Spronk, P. E., van Nidek, R. J. P. B., Bouma, W. H., & Gratama, J. W. (2006) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000240734.93460.83 · Cited by 12
Venous Thromboembolic Disease in the Elderly Patient: Atypical, Subtle, and Enigmatic
Rogers, R. L. (2007) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2007.01.013 · Cited by 12
Use of warfarin in the patient with cancer.
Pangilinan, J. M., Pangilinan, P. H., & Worden, F. P. (2007) · PubMed · Cited by 12
Differences in the INR evaluation of two different thromboplastins in patients with positivity to lupus anticoagulant in ongoing oral anticoagulation
Micco, P. D. (2010) · Journal of Blood Medicine · doi:10.2147/jbm.s8938 · Cited by 12
Hybrid treatment with angiographic catheter in massive pulmonary embolism: mechanical fragmentation and fibrinolysis
Pieri, S., & Agresti, P. (2007) · La radiologia medica · doi:10.1007/s11547-007-0191-z · Cited by 12
“linee guida suggeriscono l’impiego della frammentazione meccanica solo nelle forme di embolia più gravi [31, 32]; la nostra esperienza di trattamento ibrido, meccanico e farmacologico, dell’embolia polmonare massiva, sembra avvalorare tale impostazione: quando l’embolo non risponde subito alla frammentazione meccanica…”
Background
Valor pronóstico de la ecocardiografía transtorácica en pacientes estables hemodinámicamente con tromboembolia de pulmón aguda sintomática
Jiménez, D., Escobar, C., Sánchez, D. M., Díaz, G., Vidal, R., Taboada, D., Ortega, J. A., Moya, J. L., Barrios, V., & Sueiro, A. (2007) · Archivos de Bronconeumología · doi:10.1157/13109469 · Cited by 12
A Pilot Study of Home Treatment of Deep Vein Thrombosis With Subcutaneous Once-Daily Enoxaparin Plus Warfarin
Bishop, B., Wilson, A. G., Post, D. M., Howard, L., & Ruehlen, L. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.1.70 · Cited by 12
“For patients with acute DVT, the American College of Chest Physicians (ACCP) recommends initial treatment with SC LMWH once or twice daily over UFH, as an outpatient if possible, or as an inpatient if necessary.(21) Yet, despite the accumulating evidence for the safety and cost-effectiveness of at-home treatment with…”
Background
Inherited Thrombophilias
Coppens, M., Kaandorp, S. P., & Middeldorp, S. (2006) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2006.05.011 · Cited by 12
Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran
Harenberg, J., Jörg, I., & Weiß, C. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0076-9 · Cited by 12
“Patients with acute venous thromboembolism (VTE) require an initial treatment with an immediate acting antithrombotic agent to prevent thrombus progression and pulmonary embolism [2].”
Background
Latest medical treatment strategies for venous thromboembolism
McRae, S. J., & Eikelboom, J. W. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.9.1221 · Cited by 12
“Thrombolytic therapy compared with UFH achieves more rapid angiographic resolution of thrombus in patients with PE, [33], but increases major bleeding, which occurs in 5 – 10% of patients and causes intracranial haemorrhage in 2 – 3% of patients.”
BackgroundMethodInfluential
Changes in the technology of inferior vena cava filters promise improved benefits to the patient with less harm, but a paucity of evidence exists
Hull, R. D. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01491.x · Cited by 12
Venous Thromboembolism (VTE)
Key, N. S., & Amin, C. (2008) · Elsevier eBooks · doi:10.1016/b978-012373960-5.00669-9 · Cited by 12

Authors: Büller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., & Raskob, G. E.
Venue: Chest
Publisher: Elsevier BV
Published: 2004-09
Volume: 126
Issue: 3
Pages: 401S-428S
ISSN: 0012-3692 (ISSN-L)
DOI: 10.1378/chest.126.3_suppl.401s
OpenAlex: W2134355273
Cited by: 1,249
References: 208
Citations by year: 2025: 4 · 2024: 2 · 2023: 2 · 2022: 7 · 2021: 8 · 2020: 9 · 2019: 13 · 2018: 15 · 2017: 17 · 2016: 32 · 2015: 25 · 2014: 25 · 2013: 41 · 2012: 54
FWCI: 121.06
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: CHEST Journal (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Topics: Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
Keywords: venous thromboembolism, antithrombotic therapy, deep vein thrombosis, pulmonary embolism, low molecular weight heparin, unfractionated heparin, vitamin K antagonists, anticoagulation duration, post-thrombotic syndrome, compression stockings, thrombolysis, thromboprophylaxis
MeSH terms: Fibrinolytic Agents, Heparin, Heparin, Low-Molecular-Weight, Humans, Long-Term Care, Pulmonary Embolism, Vitamin K, Randomized Controlled Trials as Topic, Evidence-Based Medicine, International Normalized Ratio, Venous Thrombosis, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antithrombotic Therapy for Venous Thromboembolic Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks